Adenovirus
photo of adenovirus
Adenoviruses can cause a spectrum of respiratory disease as well as infection of the stomach and intestine (gastroenteritis), eyes (conjunctivitis), bladder (cystitis) and rash. Adenovirus respiratory diseases include a form of the common cold, pneumonia, croup, and bronchitis. Patients with compromised immune systems are especially susceptible to severe complications of adenovirus infection. Acute respiratory disease (ARD), a disorder first recognized among military recruits during World War II, can be caused by adenovirus infections under conditions of crowding and stress. Adenoviruses are transmitted by direct contact, fecal-oral transmission, and occasionally waterborne transmission. Some types of adenoviruses are capable of establishing persistent asymptomatic infections in the tonsils, adenoids, and intestines. Shedding of the virus can occur for months or years after the initial infection.
This is a 3 module online course (plus quiz) that will provide Military Healthcare Personnel with important and comprehensive information concerning the adenovirus vaccine.
AIG 4905 PDF 26 Jul 11
IMPLEMENTATION OF ADENOVIRUS TYPES 4 AND 7, LIVE, ORAL PROGRAM
ALARACT PDF 21 Jul 11
IMPLEMENTATION OF ADENOVIRUS TYPES 4 AND 7, LIVE, ORAL VACCINE
02 May 12

Sample Q&A: Adenovirus Types 4 and 7 Vaccine

How many doses of adenovirus vaccine are needed?
A single dose is needed, which consists of two live, oral enteric-coated tablets (type 4 - white tablet, type 7- light peach tablet). Adenovirus vaccine types 4 and 7 is administered only once and no booster dose is required.
Information on DoD Online Adenovirus Vaccine Training
Recommendations of the Armed Forces Epidemiological Board (AFEB)
Recommendations of the Armed Forces Epidemiological Board (AFEB)
Recommendations of the Armed Forces Epidemiological Board (AFEB)
After a 12-year hiatus, military recruit training centers resumed administration of adenovirus type 4 and type 7 vaccine, live, oral (adenovirus vaccine) to trainees beginning in October of 2011. Subsequently, rates of febrile respiratory illnesses (FRI) and adenovirus isolations markedly declined. These findings are consistent with those of a placebo-controlled efficacy trial conducted prior to the vaccine’s licensure by the FDA.  Continued surveillance will clarify the longer term impact of vaccine use.
ADENOVIRUS Type 4 and Type 7 LIVE, ORAL VACCINE, ADMINISTRATION COMPETENCY ASSESSMENT Patient Population Served: Recruits (17-50 yrs)
MMQC-11-1660 17 Oct 11
MANUFACTURER WILL BEGIN SHIPMENT OF THE ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE LIVE, ORAL
MMQC-11-1643 03 Oct 11
DELAY IN SHIPMENT OF THE ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE LIVE, ORAL
MMQC-11-1589 01 Sep 11
IMPLEMENTATION GUIDANCE FOR THE ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE LIVE, ORAL
VIS
Vaccine Information Statement